Key Drivers
- Strong liquidity
- Deep cash burn
- Dilutive financing
AIAI Summary
BEAM has shifted into a binary, catalyst-driven setup where the stock will likely only re-rate if BEAM-302 delivers clearly durable human data and the shares break back above 28.4, while failure would leave it as a high-burn, dilution-prone future-option story despite ample liquidity.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Deep cash burn
- •Dilutive financing
BEAM has strong liquidity and modest leverage, but persistent losses, heavy cash burn, and financing dependence make the stock look expensive relative to weak fundamentals.
Price Behavior
Key Price Behavior Insights:
- •Support defense
- •Fading momentum
- •Volatility spike
Over the last month, BEAM has drifted lower with fading momentum, holding $25.0-$25.5 support but still capped by $27.5-$28.4 resistance. ക
Sharp move from $25.07 to $28.35 shows elevated volatility
Sentiment & News
Key News Insights:
- •Clinical Milestone
- •Revenue Miss
- •Pipeline Upside
Beam Therapeutics' recent headlines show strong clinical progress and investor interest, but that momentum is being weighed by a wider quarterly loss and softer-than-expected revenue.
The news is moderately positive for Beam's long-term outlook, but near-term stock performance may remain tied to execution on trial milestones and profitability
Similar Companies in Healthcare
Other companies in the same sector with AI ratings